Is Apimeds Pharmaceuticals US, Inc (APUS) a Buy, Sell, or Hold?
AMEX : APUS
Apimeds Pharmaceuticals US, Inc
$0.655 USD
-$0.05 (-7.47%)
- Volume
- 19.84K
- Average Volume
- 189.45K
- Market Capitalization
- $823.73K
- P/E Ratio
- -0.11
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $40.31
- Year Low
- $0.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.90
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Vinod Menon |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | APUS |
| CUSIP | 03771D102 |
| CIK | 0001894525 |
| Web | https://www.apimedsus.com |
| Phone | 808-209-7887 |
| Currency | USD |
| Employees | 7 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.08 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.90 |
| Quick Ratio | 0.90 |
| Cash Ratio | 0.07 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.72 |
| Price / Cash Flow | -0.08 |
| Price / Book | 0.08 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.55 |
| Trailing P/E Ratio | -0.11 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$6M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -54.62% |
| Return on Assets | -28.79% |
Financials Score
| AltmanZ Score | -1.35 |
| Piotroski Score | 3.00 |
| Working Capital | -1.43M |
| Total Assets | 141.22M |
| Ebit | -39.55M |
| Market Cap | 900.19K |
| Total Liabilities | 14.7M |
Poll Results
About Apimeds Pharmaceuticals US, Inc (AMEX:APUS) Stock
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc. ...
2026-06-08 09:00:00
Recognition Reflects Dedication, Collaboration, and Purpose-Driven Culture thatEmpower University Employees to Make Last Impacts on Global Students CHARLES TOWN, W.Va., June 8, 2026 /PRNewswire/ -- American Public University System (APUS) has again been certified as a Great Place to Work® , a recognition earned entirely through positive employee feedback.
2026-05-05 14:07:00
MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee Parties”), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement.
2026-04-26 20:12:11
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc. ("Apimeds" or "the Company") (NYSE American: APUS) for violations of the securities laws.
2026-04-26 20:12:00
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc. (“Apimeds” or “the Company”) (NYSE American: APUS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2026-04-16 10:14:00
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) resulting from allegations that Apimeds may have issued materially misleading business information to the investing public. So what: If you purchased Apimeds securities you may be entitled to compensation without payment of any out of pocket fees or costs through a continge.
Frequently Asked Questions
-
What is the current Apimeds Pharmaceuticals US, Inc (APUS) stock price?
-
Apimeds Pharmaceuticals US, Inc(AMEX:APUS) stock price is $0.655 in the last trading session. During the trading session, APUS stock reached the peak price of $40.31 while $0.6403 was the lowest point it dropped to. The percentage change in APUS stock occurred in the recent session was --7.47% while the dollar amount for the price change in APUS stock was -$0.05.
-
APUS's industry and sector of operation?
-
The AMEX listed APUS is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of APUS?
-
Amardeep Singh | Chief Technology Officer
Vinod Menon | Founder & Co-CEO
Erick J. Frim | Chief Financial Officer
Erik C. Emerson | President
Captain Sandeep Yadav | Chief Operating Officer -
How many employees does APUS have?
-
Number of APUS employees currently stands at 7. APUS operates from 2 East Broad Street, Hopewell, NJ 08525, US.
-
Link for APUS official website?
-
Official Website of APUS is: https://www.apimedsus.com
-
How do I contact APUS?
-
APUS could be contacted at phone #808-209-7887 and can also be accessed through its website. APUS operates from 2 East Broad Street, Hopewell, NJ 08525, US.
-
How many shares of APUS are traded daily?
-
The average number of APUS shares traded daily for last 3 months was 189.45K.
-
What is the market cap of APUS currently?
-
The market value of APUS currently stands at $823.73K with its latest stock price at $0.655